Skip to main content
SpringerLink
Log in

News from ISPOR: economics of emicizumab evaluated

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Godard C, et al. Cost-Effectiveness of Emicizumab Versus by-Passing Agents in Patients with Haemophilia a and Fviii Inhibitors in France. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRO34, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/96183

  2. Cortesi PA, et al. Emicizumab Prophylaxis in Haemophilia a Patients with Inhibitors- a Cost-Effectiveness and Budget Impact Analysis. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO28, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97735

  3. Soares V, et al. Cost-Effectiveness Analysis of Emicizumab for the Treatment of Patients with Haemophilia a with Inhibitors in Portugal. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSY21, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3118/94847

  4. Guler B, et al. Cost Minimization Analysis of Emicizumab in the Prophylaxis of Inhibitor-Negative Patients with Hemophilia a in Turkey. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO57, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/95540

  5. Souza P, et al. Cost-Effectiveness Analysis of Emicizumab Versus Bypassing Agents in Patients with Hemophilia a with Inhibitors in the Brazilian Public Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO38, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97736

  6. Souza P, et al. Budget Impact Analysis of Emicizumab Prophylaxis for Haemophilia a Patients with Inhibitors in the Brazilian Public Healthcare System Perspective. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO36, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/98700

  7. Lee H, et al. Emicizumab Prophylaxis is a Cost-Saving Option for Hemophilia a Patients with Inhibitors in Korea- a Cost-Effectiveness Analysis. 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PRO46, 2 Nov 2019. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/94038

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

News from ISPOR: economics of emicizumab evaluated. PharmacoEcon Outcomes News 842, 20–21 (2019). https://doi.org/10.1007/s40274-019-6412-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6412-6

Search

Navigation